Breast cancer Cancer Breast
Conditions
Interventions
Control Arm A: 5- Fluorouracil (5-FU) (600 mg/m^2 intravenous [iv] bolus), Epirubicin (60 mg/m^2 iv bolus), Cyclophosphamide (600 mg/m^2 iv bolus) x eight cycles at three weekly intervals.
Control Ar
Sponsors
Sponsor not defined - Record supplied by Institute of Cancer Research
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients with operable histologically confirmed completely resected invasive breast cancer for whom adjuvant chemotherapy is indicated 2. No clinical or radiological evidence of locoregional or metastatic disease based on standard staging procedures at local centres 3. World Health Organisation (WHO) performance status of zero or one 4. Chemotherapy to start within eight weeks from date of definitive surgery 5. Aged over 18 years (no upper age limit) 6. Hormone receptor status to be determined prior to randomisation 7. Adequate renal, hepatic and bone marrow function 8. Signed written informed consent
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed